{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:57:25Z","timestamp":1740124645971,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,3,22]]},"DOI":"10.1038\/s41388-017-0031-0","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T12:13:26Z","timestamp":1515500006000},"page":"1594-1609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-9298","authenticated-orcid":false,"given":"Gerjon J.","family":"Ikink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira R. M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel","family":"Vendel-Zwaagstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"ten Hoeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Jonkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewyk F.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hilkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-013-2647-2","volume":"140","author":"MJ Engstr\u00f8m","year":"2013","unstructured":"Engstr\u00f8m MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013;140:1\u201311.","journal-title":"Breast Cancer Res Treat"},{"key":"31_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","volume":"28","author":"S Dawood","year":"2010","unstructured":"Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92\u20138.","journal-title":"J Clin Oncol"},{"key":"31_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124\u201330.","journal-title":"J Clin Oncol"},{"key":"31_CR4","doi-asserted-by":"crossref","first-page":"64431","DOI":"10.18632\/oncotarget.7043","volume":"5","author":"DDM Gagliato","year":"2016","unstructured":"Gagliato DDM, Jardim DLF, Marchesi MSP, Hortobagyi GN, de Melo Gagliato D, Leonardo Fontes Jardim D, et al. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;5:64431\u201346.","journal-title":"Oncotarget"},{"key":"31_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0092-8674(88)90184-5","volume":"54","author":"WJ Muller","year":"1988","unstructured":"Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P, Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988;54:105\u201315.","journal-title":"Cell"},{"key":"31_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/0092-8674(89)90331-0","volume":"57","author":"L Bouchard","year":"1989","unstructured":"Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV\/c-neu oncogene. Cell. 1989;57:931\u20136.","journal-title":"Cell"},{"key":"31_CR7","doi-asserted-by":"publisher","first-page":"10578","DOI":"10.1073\/pnas.89.22.10578","volume":"89","author":"CT Guy","year":"1992","unstructured":"Guy CT, Webster Ma, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci Usa 1992;89:10578\u201382.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"31_CR8","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1073\/pnas.97.7.3444","volume":"97","author":"ER Andrechek","year":"2000","unstructured":"Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. Amplification of the neu\/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA. 2000;97:3444\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"31_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0002-9440(10)64269-1","volume":"161","author":"A Rosner","year":"2002","unstructured":"Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, et al. Pathway pathology: histological differences between ErbB\/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol. 2002;161:1087\u201397.","journal-title":"Am J Pathol"},{"key":"31_CR10","first-page":"4920","volume":"63","author":"ER Andrechek","year":"2003","unstructured":"Andrechek ER, Laing MA, Girgis-Gabardo AA, Siegel PM, Cardiff RD, Muller WJ. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res 2003;63:4920\u20136.","journal-title":"Cancer Res"},{"key":"31_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ng2034","volume":"39","author":"V Theodorou","year":"2007","unstructured":"Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, Jonkers J, et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 2007;39:759\u201369.","journal-title":"Nat Genet"},{"key":"31_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027425","volume":"6","author":"HH Kim","year":"2011","unstructured":"Kim HH, van den Heuvel APJ, Schmidt JW, Ross SR. Novel common integration sites targeted by mouse mammary tumor virus insertion in mammary tumors have oncogenic activity. PLoS One 2011;6:e27425.","journal-title":"PLoS One"},{"key":"31_CR13","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.18632\/oncotarget.682","volume":"3","author":"R Callahan","year":"2012","unstructured":"Callahan R, Mudunur U, Bargo S, Raafat A, McCurdy D, Boulanger C, et al. Genes affected by mouse mammary tumor virus (MMTV) proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors. Oncotarget. 2012;3:1320\u201334.","journal-title":"Oncotarget"},{"key":"31_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062113","volume":"8","author":"C Klijn","year":"2013","unstructured":"Klijn C, Koudijs MJ, Kool J, ten Hoeve J, Boer M, de Moes J, et al. Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors. PLoS One 2013;8:e62113.","journal-title":"PLoS One"},{"key":"31_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13567","volume":"7","author":"GJ Ikink","year":"2016","unstructured":"Ikink GJ, Boer M, Bakker ERM, Hilkens J. IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K\/AKT-pathway hyperactivation. Nat Commun. 2016;7:13567.","journal-title":"Nat Commun"},{"key":"31_CR16","first-page":"43","volume-title":"Current Topics in Microbiology and Immunology","author":"R. Nusse","year":"1991","unstructured":"Nusse R. Insertional mutagenesis in mouse mammary tumorigenesis. In: Kung H-J, Vogt P, editors. Retroviral insertion and oncogene activation. Berlin: Springer; 1991. p. 43\u201365."},{"key":"31_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1376","volume":"8","author":"J Hilkens","year":"2006","unstructured":"Hilkens J. Recent translational research: oncogene discovery by insertional mutagenesis gets a new boost. Breast Cancer Res 2006;8:102.","journal-title":"Breast Cancer Res"},{"key":"31_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10911-008-9092-6","volume":"13","author":"R Callahan","year":"2008","unstructured":"Callahan R, Smith GH. Common integration sites for MMTV in viral induced mouse mammary tumors. J Mammary Gland Biol Neoplasia 2008;13:309\u201321.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"31_CR19","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1101\/gr.112763.110","volume":"21","author":"MJ Koudijs","year":"2011","unstructured":"Koudijs MJ, Klijn C, Van Der Weyden L, Kool J, Ten Hoeve J, Sie D, et al. High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome Res 2011;21:2181\u20139.","journal-title":"Genome Res"},{"key":"31_CR20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/nar\/12.4.1821","volume":"12","author":"J Miyoshi","year":"1984","unstructured":"Miyoshi J, Kagimoto M, Soeda E, Sakaki Y. The human c-Ha-ras2 is a processed pseudogene inactivated by numerous base substitutions. Nucleic Acids Res 1984;12:1821\u20138.","journal-title":"Nucleic Acids Res"},{"key":"31_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature01646","volume":"423","author":"K Takahashi","year":"2003","unstructured":"Takahashi K, Mitsui K, Yamanaka S, Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature. 2003;423:541\u20135.","journal-title":"Nature"},{"key":"31_CR22","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2012.11.039","volume":"151","author":"JM Polo","year":"2012","unstructured":"Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012;151:1617\u201332.","journal-title":"Cell"},{"key":"31_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/stem.1447","volume":"32","author":"Y Yu","year":"2014","unstructured":"Yu Y, Liang D, Tian Q, Chen X, Jiang B, Chou BK, et al. Stimulation of somatic cell reprogramming by ERas-Akt-FoxO1 signaling axis. Stem Cells 2014;32:349\u201363.","journal-title":"Stem Cells"},{"issue":"8","key":"31_CR24","doi-asserted-by":"publisher","first-page":"150092","DOI":"10.1098\/rsob.150092","volume":"5","author":"Zhen-Ao Zhao","year":"2015","unstructured":"Zhao Z-A, Yu Y, Ma H-X, Wang X-X, Lu X, Zhai Y, et al. The roles of ERAS during cell lineage specification of mouse early embryonic development. Open Biol. 2015; 5: 150092. https:\/\/doi.org\/10.1098\/rsob.150092.","journal-title":"Open Biology"},{"key":"31_CR25","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkh013","volume":"32","author":"K Akagi","year":"2004","unstructured":"Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004;32:D523\u201327.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"31_CR26","doi-asserted-by":"publisher","first-page":"e1279722","DOI":"10.1080\/23723556.2017.1279722","volume":"4","author":"Gerjon J. Ikink","year":"2017","unstructured":"Ikink GJ, Hilkens J, Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance. Mol Cell Oncol. 2017;4:e1279722.","journal-title":"Molecular & Cellular Oncology"},{"key":"31_CR27","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci Usa 2003;100:8933\u20138.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"31_CR28","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878\u201387.","journal-title":"Cancer Res"},{"key":"31_CR29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","volume":"163","author":"G Ciriello","year":"2015","unstructured":"Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506\u201319.","journal-title":"Cell"},{"key":"31_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 2016;7:11479.","journal-title":"Nat Commun"},{"key":"31_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395\u2013402.","journal-title":"Cancer Cell"},{"key":"31_CR32","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","volume":"68","author":"PJA Eichhorn","year":"2008","unstructured":"Eichhorn PJA, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221\u201330.","journal-title":"Cancer Res"},{"key":"31_CR33","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","volume":"33","author":"IJ Majewski","year":"2015","unstructured":"Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 2015;33:1334\u20139.","journal-title":"J Clin Oncol"},{"key":"31_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mcn.2008.05.019","volume":"39","author":"PY Wang","year":"2008","unstructured":"Wang PY, Seabold GK, Wenthold RJ. Synaptic adhesion-like molecules (SALMs) promote neurite outgrowth. Mol Cell Neurosci. 2008;39:83\u201394.","journal-title":"Mol Cell Neurosci"},{"key":"31_CR35","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1523\/JNEUROSCI.4839-09.2010","volume":"30","author":"W Mah","year":"2010","unstructured":"Mah W, Ko J, Nam J, Han K, Chung WS, Kim E. Selected SALM (synaptic adhesion-like molecule) family proteins regulate synapse formation. J Neurosci. 2010;30:5559\u201368.","journal-title":"J Neurosci"},{"issue":"11","key":"31_CR36","doi-asserted-by":"publisher","first-page":"e113489","DOI":"10.1371\/journal.pone.0113489","volume":"9","author":"Irina Vyazunova","year":"2014","unstructured":"Vyazunova I, Maklakova VI, Berman S, De I, Steffen MD, Hong W, et al. Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis. PLoS ONE. 2014;9:e113489..","journal-title":"PLoS ONE"},{"key":"31_CR37","doi-asserted-by":"crossref","first-page":"RE13","DOI":"10.1126\/stke.2502004re13","volume":"2004","author":"J Colicelli","year":"2004","unstructured":"Colicelli J. Human RAS superfamily proteins and related GTPases. Sci Stke 2004;2004:RE13.","journal-title":"Sci Stke"},{"key":"31_CR38","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1634\/stemcells.2005-0054","volume":"23","author":"T Kameda","year":"2005","unstructured":"Kameda T, Thomson JA. Human ERas gene has an upstream premature polyadenylation signal that results in a truncated, noncoding transcript. Stem Cells 2005;23:1535\u201340.","journal-title":"Stem Cells"},{"key":"31_CR39","first-page":"2189","volume":"29","author":"R Kaizaki","year":"2009","unstructured":"Kaizaki R, Yashiro M, Shinto O, Yasuda K, Matsuzaki T, Sawada T, et al. Expression of ERas oncogene in gastric carcinoma. Anticancer Res 2009;29:2189\u201393.","journal-title":"Anticancer Res"},{"key":"31_CR40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2353\/ajpath.2010.091056","volume":"177","author":"E Kubota","year":"2010","unstructured":"Kubota E, Kataoka H, Aoyama M, Mizoshita T, Mori Y, Shimura T, et al. Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric cancer. Am J Pathol. 2010;177:955\u201363.","journal-title":"Am J Pathol"},{"key":"31_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","volume":"21","author":"NE Hynes","year":"2009","unstructured":"Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177\u201384.","journal-title":"Curr Opin Cell Biol"},{"key":"31_CR42","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/0008-5472.CAN-03-0173","volume":"64","author":"KL Knutson","year":"2004","unstructured":"Knutson KL, Almand B, Dang Y, Disis ML. neu Antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004;64:1146\u201351.","journal-title":"Cancer Res"},{"key":"31_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/2159-8290.CD-12-0462","volume":"3","author":"MJ Ellis","year":"2013","unstructured":"Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013;3:27\u201334.","journal-title":"Cancer Discov"},{"key":"31_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117\u201327.","journal-title":"Cancer Cell"},{"key":"31_CR45","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","volume":"177","author":"FJ Esteva","year":"2010","unstructured":"Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177:1647\u201356.","journal-title":"Am J Pathol"},{"key":"31_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-248","volume":"11","author":"L Wang","year":"2011","unstructured":"Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 2011;11:248.","journal-title":"BMC Cancer"},{"key":"31_CR47","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1158\/1078-0432.CCR-12-1785","volume":"18","author":"S Chandarlapaty","year":"2012","unstructured":"Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012;18:6784\u201391.","journal-title":"Clin Cancer Res"},{"key":"31_CR48","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1073\/pnas.1303204110","volume":"110","author":"AB Hanker","year":"2013","unstructured":"Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, S\u00e1nchez V, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA. 2013;110:14372\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"31_CR49","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3892\/ijo_00000752","volume":"37","author":"M Aoyama","year":"2010","unstructured":"Aoyama M, Kataoka H, Kubota E, Tada T, Asai K. Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells. Int J Oncol 2010;37:1011\u20136.","journal-title":"Int J Oncol"},{"key":"31_CR50","first-page":"3353","volume":"31","author":"E Kubota","year":"2011","unstructured":"Kubota E, Kataoka H, Tanaka M, Okamoto Y, Ebi M, Hirata Y, et al. ERas enhances resistance to CPT-11 in gastric cancer. Anticancer Res 2011;31:3353\u201360.","journal-title":"Anticancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-017-0031-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-017-0031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-017-0031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T01:16:19Z","timestamp":1660266979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-017-0031-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,3,22]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1038\/s41388-017-0031-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"type":"print","value":"0950-9232"},{"type":"electronic","value":"1476-5594"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"6 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}